Leiden, The Netherlands, 7 January 2009 - Dutch biopharmaceutical
company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss
Exchange: CRX) today confirms that it is in friendly discussions with
Wyeth that may lead to a combination of the two
companies. These discussions are at a preliminary stage and there is
no certainty that they will result in a transaction. An
update will be provided in due course.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a
global biopharmaceutical company focused on research,
development, production and marketing of vaccines, proteins and
antibodies that prevent and treat infectious diseases. Its
vaccines are sold in public and private markets worldwide. Crucell's
core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases and a
virosome-adjuvanted vaccine against influenza. Crucell
also markets travel vaccines, such as the only oral anti-typhoid
vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad
development pipeline, with several product candidates based on
its unique PER.C6® production technology. The Company licenses its
PER.C6® technology and other technologies to the
biopharmaceutical industry. Important partners and licensees include
DSM Biologics, sanofi-aventis, Novartis, Wyeth and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Switzerland, Spain, Portugal, Italy,
Sweden, Korea and the US. The Company employs over a 1000 people. For
more information, please visit www.crucell.com.

Forward-looking statements
This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified
certain important factors that may cause actual results to differ
materially from those contained in such forward-looking
statements. For information relating to these factors please refer to
our Form 20-F, as filed with the U.S. Securities and
Exchange Commission on May 7, 2008, and the section entitled "Risk
Factors". The Company prepares its financial statements
under International Financial Reporting Standards (IFRS).

For further information please contact:

Crucell N.V.
Oya Yavuz
Director Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
ir@crucell.com
www.crucell.com


This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.
http://hugin.info/132631/R/1280875/286282.pdf


Copyright © Hugin AS 2009. All rights reserved.